Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00478686 · ClinicalTrials.gov registry record
Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 102
- Enrollment target
NCT00478686: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00478686 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 102 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00478686 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 102 participants
- Enrollment target
Study Summary
The goal of this laboratory research study is to identify possible differences in a gene among patients with breast cancer that cannot be treated by surgery. Researchers want to find out if differences in this gene may increase the risk of side effects from capecitabine.
Interventions
- PROCEDURE Phlebotomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2007-05-23 |
| Est. Completion | 2017-05-02 |
What the finished NCT00478686 record still lists
NCT00478686 is an observational study that tracks outcomes without assigning an intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Phlebotomy is the first listed.
NCT00478686 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00478686 about?
NCT00478686 is a clinical study titled "Association of Dihydropyrimidine Dehydrogenase (DPYD) Variants With Toxicity Related to Capecitabine". The goal of this laboratory research study is to identify possible differences in a gene among patients with breast cancer that cannot be treated by surgery. Researchers want to find out if differences in this gene may increase the risk of side effects from capecitabine.
What is the current status of trial NCT00478686?
This trial is currently completed. The enrollment target is 102 participants. The study started on 2007-05-23. Estimated completion is 2017-05-02.
What interventions are being tested in trial NCT00478686?
The interventions under investigation include: Phlebotomy (PROCEDURE).
Who is sponsoring clinical trial NCT00478686?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI